Since GSDME cleavage by caspase-3 mediates both pyroptosis and apoptosis [32], while the caspase-3/7-specific cleavage inactivates GSDMD and therefore inhibits pyroptosis [30], our results suggest that combination treatment induces concurrent strong apoptotic and variable levels of GSDME-dependent pyroptotic cell death in CML cell lines. The gene discussed is CASP3; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.